The global Neurology Clinical Trials Market was valued at around US$ 5.4 billion in 2021. With a projected CAGR of 6.3% for the next ten years, the market is likely to reach a valuation of nearly US$ 10.5 billion by the end of 2032. The neurology clinical trials market is expected to achieve an absolute dollar opportunity growth of US$ 4.8 billion over the forecasted period.
| Attributes | Details |
|---|---|
| Neurology Clinical Trials Market Size (2021A) | US$ 5.4 billion |
| Neurology Clinical Trials Market Size (2022E) | US$ 5.7 billion |
| Projected Market Value (2032F) | US$ 10.5 billion |
| Global Market Growth Rate (2022 to 2032) | 6.3% CAGR |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Future Market Insights reveals that Interventional study design led the market for neurology clinical trials. Market revenue through interventional study design grew at 5.6% CAGR from 2017 to 2021. While Huntington’s disease maintained the top Indication in neurology, clinical trials with a growth rate of 5.2% from 2017 to 2021.
The market is likely to grow due to an increase in global neurological disorders. This will drive the market for government spending and collaboration from pharmaceutical companies for the collaboration of new drugs and medication.
According to Lancet medical journal, total disability life adjusted years (DALYs) from, non-communicable neurological disorders like stroke, Alzheimer’s disease, dementia, Parkinson’s disease, and headache disorders increased in India and contributed 82.8% in 2019. Neurological disorders like stroke contributed to the highest share of deaths in India followed by Alzheimer’s. Based on the study, changes in lifestyle habits were a substantial contributor to non-communicable diseases. For instance, high systolic blood pressure, air pollution, and dietary factor contributed to 55.3%, 42.2%, and 28.1% respectively strokes.
The requirement for neurology clinical trials is soaring, but several pharmaceutical companies are leaving the market due to the high cost of clinical trials across therapeutic areas and the high failure rates of clinical trials. Based on the Tufts Center for the Study of Drug Development, CNS drugs take 18% more time to develop when compared to other drugs, and only 6% of drugs are finally approved out of clinical testing. These statistics are discouraging enough for pharmaceutical companies not to invest in neurological clinical trials.
In order to make the transition from Phase I to Phase II trial, companies require data packages to enhance upcoming investments. Few academic and market scientists refuse to share data resulting in a delay in clinical trials.
On the other hand, diagnosis of the central nervous system (CNS) is studied on the basis of symptoms, and signs, and the reasons are varied in different patients within existing diagnostic categories. This makes the identification of the problem difficult.
Moreover, animal models have not shown effective predictive validity and reproducibility. Animal models of CNS disorders are less understood and are not able to recreate the varied neurological human disorders on their model.
Principal Consultant
With the rise in neurological diseases, such as Alzheimer’s disease and Huntington's disease neuroscience remains a key domain for the majority of investments due to the high societal and monetary burden. Pharma and medical device companies have joined hands to offer better understanding and improved treatment. Moreover, the unprecedented rise in neurological disorders has called for the government to support funding for neurology clinical trials.
Scientists at the University of Sheffield’s Neuroscience Institute and NIHR Sheffield Biomedical Research Centre received funding of US$ 61 Million from the government to bring suitable treatment options for motor neuron disease (MillionD). The funding is expected to change the clinical trials in the coming years.
The government of Australia invested US$ 21.8 Million for the treatment of varied neurological disorders. Around 10 research projects were earmarked in Australia for the treatment of Supranuclear palsy and attempts would be made to reduce fatigue in patients after a stroke. Furthermore, the Clinical Trials Activity Initiative by the Australian Government aims to provide US$ 750 Million over 10 years from 2022 to 23 to Australian researchers in order to increase clinical trials in the country.
The total number of DALYs resulting from neurological disorders was 21 million in the European Union, in 2017 and 41.1 million in WHO European region. A substantial burden will likely catch the attention of neurological clinical trials in Europe.
Development in the healthcare system has extended life expectancy. An increase in the older population has also come up with the burden of non-communicable neurological diseases which is the main driver for spending in neurology clinical trials in Europe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for neurology clinical trials in the USA is valued at USA$ 3.7 billion by 2032. Revenue through neurology clinical trials grew at 5.3% CAGR from 2017 to 2021. The USA contributes to a vast number of neurological patients which drives the need for expanding clinical trials. In 2020, 5.8 million Americans suffered from Alzheimer’s disease. This number is projected to triple to 14 million by 2060.
Companies like Biogen and IQVIA have continuously advanced in innovating new drugs and receiving FDA approvals for neurological disorders in America. Government agencies like the National Institute of Neurological Disorders and Stroke fund clinical trials and numerous research programs to reduce the burden of neurological disorders in the USA. The absolute dollar opportunity growth in the USA is expected to be at USA$ 1.8 billion during the forecasted period of 2022 to 2032.
The market for neurology clinical trials in the United Kingdom was valued at USA$ 226 million in 2021. With an absolute dollar opportunity of USA$ 254 million, the market in the country is projected to reach a valuation of USA$ 493 million by 2032. From 2022 to 2032, the market in the United Kingdom is projected to grow at a CAGR of 7.6%.
In Japan, the neurology clinical trials market in Japan was held at USA$ 179 million in 2021. By 2032, the market in Japan is expected to reach a valuation of USA$ 338 million. Growing at a CAGR of 5.7% from 2022 to 2032, the market in the country is likely to gross an absolute dollar opportunity of USA$ 145 million.
The neurology clinical trials market in South Korea is expected to be valued at USA$ 192 million by 2032. With a CAGR of 5.9%, the market in South Korea is expected to gross an absolute dollar opportunity of USA$ 84 million during the forecast period.
Interventional study design dominated the market for neurology clinical trials and accounted for a 5.6% CAGR from 2017 to 2021. It is expected to grow at a rate of 6.5% during the forecasted period. The interventional study design is preferable in most clinical trials due to its safety and cost-effectiveness and acceptability of the Intervention. Interventional study design assists in gauging the direct impact on treatments or prevention of neurological diseases.
Health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in Research and Development (R&D), and inventing new drugs for the treatment of neurological disorders. The key companies operating in the neurology clinical trials market include Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora Healthcare, Biogen, and IQVIA.
Some of the recent developments by key providers of neurology clinical trials are as follows:
Similarly, recent developments related to companies involved in Neurology Clinical Trials have been tracked by the team at Future Market Insights, which is available in the full report.
The global Neurology Clinical Trials market was valued at US$ 5.4 billion in 2021 and US$ 5.7 billion in 2022.
The Neurology Clinical Trials industry is set to witness a high growth rate of 5.4% over the forecast period and is valued at US$ 10.5 by 2032.
Interventional study design maintained its largest share by 5.6% CAGR in 2021 and is expected to grow at 6.5% CAGR during the forecasted period of 2022 to 2032.
Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora healthcare, Biogen and IQVIA are the key companies operating in Neurology Clinical Trials Market
Huntington’s disease dominates the market for neurology clinical trials with 5.2% CAGR during 2017 to 2021. Anticipated growth rate of Huntington’s disease is 6.0% during the forecasted period.
The USA, The United Kingdom., China, Japan, and South Korea are expected to drive the most sales growth of neurology clinical trials
The neurology clinical trials market in the USA is valued at US$ 3.7 billion in 2032 and is expected to achieve a growth rate of 6.6% during the forecasted year.
1. Executive Summary | Neurology Clinical Trials Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Investment Feasibility Matrix
3.4. Regulatory Landscape
3.4.1. By Key Regions
3.4.2. By Key Countries
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2022 to 2032
5.3.1. Phase I
5.3.2. Phase II
5.3.3. Phase III
5.3.4. Phase IV
5.4. Y-o-Y Growth Trend Analysis By Phase, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Phase, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Study Design, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Study Design, 2022 to 2032
6.3.1. Interventional
6.3.2. Observational
6.3.3. Expanded Access
6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Study Design, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032
7.3.1. Epilepsy
7.3.2. Parkinson's Disease (PD)
7.3.3. Huntington's Disease
7.3.4. Stroke
7.3.5. Traumatic Brain Injury (TBI)
7.3.6. Amyotrophic Lateral Sclerosis (ALS)
7.3.7. Muscle regeneration
7.3.8. Other Indications
7.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia
8.3.6. Oceania
8.3.7. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Phase
9.2.3. By Study Design
9.2.4. By Indication
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Phase
9.3.3. By Study Design
9.3.4. By Indication
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Argentina
10.2.1.4. Rest of Latin America
10.2.2. By Phase
10.2.3. By Study Design
10.2.4. By Indication
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Phase
10.3.3. By Study Design
10.3.4. By Indication
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. The United Kingdom
11.2.1.5. Spain
11.2.1.6. Russia
11.2.1.7. BENELUX
11.2.1.8. Rest of Europe
11.2.2. By Phase
11.2.3. By Study Design
11.2.4. By Indication
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Phase
11.3.3. By Study Design
11.3.4. By Indication
11.4. Key Takeaways
12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Phase
12.2.3. By Study Design
12.2.4. By Indication
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Phase
12.3.3. By Study Design
12.3.4. By Indication
12.4. Key Takeaways
13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Thailand
13.2.1.3. Malaysia
13.2.1.4. Indonesia
13.2.1.5. Rest of South Asia
13.2.2. By Phase
13.2.3. By Study Design
13.2.4. By Indication
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Phase
13.3.3. By Study Design
13.3.4. By Indication
13.4. Key Takeaways
14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Phase
14.2.3. By Study Design
14.2.4. By Indication
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Phase
14.3.3. By Study Design
14.3.4. By Indication
14.4. Key Takeaways
15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. Rest of MEA
15.2.2. By Phase
15.2.3. By Study Design
15.2.4. By Indication
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Phase
15.3.3. By Study Design
15.3.4. By Indication
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. The USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Phase
16.1.2.2. By Study Design
16.1.2.3. By Indication
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Phase
16.2.2.2. By Study Design
16.2.2.3. By Indication
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Phase
16.3.2.2. By Study Design
16.3.2.3. By Indication
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Phase
16.4.2.2. By Study Design
16.4.2.3. By Indication
16.5. Argentina
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Phase
16.5.2.2. By Study Design
16.5.2.3. By Indication
16.6. Germany
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Phase
16.6.2.2. By Study Design
16.6.2.3. By Indication
16.7. Italy
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Phase
16.7.2.2. By Study Design
16.7.2.3. By Indication
16.8. France
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Phase
16.8.2.2. By Study Design
16.8.2.3. By Indication
16.9. The United Kingdom
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Phase
16.9.2.2. By Study Design
16.9.2.3. By Indication
16.10. Spain
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Phase
16.10.2.2. By Study Design
16.10.2.3. By Indication
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Phase
16.11.2.2. By Study Design
16.11.2.3. By Indication
16.12. BENELUX
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Phase
16.12.2.2. By Study Design
16.12.2.3. By Indication
16.13. China
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Phase
16.13.2.2. By Study Design
16.13.2.3. By Indication
16.14. Japan
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Phase
16.14.2.2. By Study Design
16.14.2.3. By Indication
16.15. South Korea
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Phase
16.15.2.2. By Study Design
16.15.2.3. By Indication
16.16. India
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Phase
16.16.2.2. By Study Design
16.16.2.3. By Indication
16.17. Thailand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Phase
16.17.2.2. By Study Design
16.17.2.3. By Indication
16.18. Malaysia
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Phase
16.18.2.2. By Study Design
16.18.2.3. By Indication
16.19. Indonesia
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Phase
16.19.2.2. By Study Design
16.19.2.3. By Indication
16.20. Australia
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Phase
16.20.2.2. By Study Design
16.20.2.3. By Indication
16.21. New Zealand
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2021
16.21.2.1. By Phase
16.21.2.2. By Study Design
16.21.2.3. By Indication
16.22. GCC Countries
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2021
16.22.2.1. By Phase
16.22.2.2. By Study Design
16.22.2.3. By Indication
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Phase
17.3.3. By Study Design
17.3.4. By Indication
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. IQVIA
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Novartis
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Covance
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Medpace
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Charles River Laboratories
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. GlaxoSmithKline
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Aurora Healthcare
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Biogen
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Neurology Clinical Trials Market
